{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:01:41Z","timestamp":1747184501031,"version":"3.40.5"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1111\/ejh.13479","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T10:25:20Z","timestamp":1593253520000},"page":"662-666","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Myeloma care adaptations in the UK during SARS\u2010CoV\u20102 pandemic: Challenges and measurable outcomes"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-7632","authenticated-orcid":false,"given":"Faouzi","family":"Djebbari","sequence":"first","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotios","family":"Panitsas","sequence":"additional","affiliation":[{"name":"Department of Haematology Laiko General Hospital  Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faye A.","family":"Sharpley","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Rampotas","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jemma","family":"Larham","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31240-X"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31173-9"},{"key":"e_1_2_13_4_1","unstructured":"Public Health England.Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID\u201019. 2020. Available athttps:\/\/www.gov.uk\/government\/publications\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19\/guidance-on-shielding-and-protecting-extremely-vulnerable-persons-from-covid-19. Last Accessed April 21 2020"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16874"},{"key":"e_1_2_13_6_1","unstructured":"British Society of Haematology (BSH).UK Myeloma Forum guidance to support medical decision\u2010making in the management of myeloma patients during the COVID\u201019 (Coronavirus) outbreak. 2020. Available athttps:\/\/b-s-h.org.uk\/media\/18178\/covid_19_ukmf_guidance_document_final_24th_march_2020.pdf. Last Accessed April 21 2020."},{"key":"e_1_2_13_7_1","unstructured":"European Society of Medical Oncology (ESMO).ESMO management and treatment adapted recommendations in the COVID\u201019 era: Multiple myeloma. Available athttps:\/\/www.esmo.org\/guidelines\/cancer-patient-management-during-the-covid-19-pandemic\/haematological-malignancies-multiple-myeloma-in-the-covid-19-era. Last Accessed April 21 2020"},{"key":"e_1_2_13_8_1","unstructured":"European Society for Blood and Marrow Transplantation (EBMT).Coronavirus disease COVID\u201019(7th April 2020). Available athttps:\/\/www.ebmt.org\/sites\/default\/files\/2020-04\/EBMT-COVID-19-guidelines_v.6.1%282020-04-07%29.pdf. Last Accessed April 21 2020"},{"key":"e_1_2_13_9_1","unstructured":"International Myeloma Society (IMS).International Myeloma Society Recommendations for the Management of Myeloma Patients During the COVID\u201019 Pandemic. 2020. Available athttps:\/\/cms.cws.net\/content\/beta.myelomasociety.org\/files\/IMS%20recommendations%20for%20Phy. Last Accessed April 21 2020"},{"key":"e_1_2_13_10_1","first-page":"1","article-title":"Management of patients with multiple myeloma in the era of COVID\u201019 pandemic: a consensus paper from the European Myeloma Network (EMN)","author":"Terpos E","year":"2020","journal-title":"Leukemia"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16620"},{"key":"e_1_2_13_12_1","unstructured":"National Institute for Health and Care Excellence.COVID\u201019 rapid guideline: delivery of systemic anticancer treatments.2020a. Available athttps:\/\/www.nice.org.uk\/guidance\/ng161\/resources\/covid19-rapid-guideline-delivery-of-systemic-anticancer-treatments-pdf-66141895710661. Last Accessed April 21 2020"},{"key":"e_1_2_13_13_1","unstructured":"National Institute for Health and Care Excellence.Interim treatment change options during the COVID\u201019 pandemic endorsed by NHS England.2020b. Available athttps:\/\/www.nice.org.uk\/guidance\/ng161\/resources\/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. Last Accessed April 21 2020"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.088211"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1022"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.01.014"},{"key":"e_1_2_13_17_1","unstructured":"Summary of Products Characteristics.DARZALEX 1 800 mg solution for injection. Available athttps:\/\/www.medicines.org.uk\/emc\/product\/11488\/smpc. Last Accessed June15 2020"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16324"},{"key":"e_1_2_13_19_1","unstructured":"International Society of Amyloidosis.International Society of Amyloidosis recommendations on the management of patients with systemic amyloidosis during the COVID\u201019 pandemic. 2020. Available athttps:\/\/cms.cws.net\/content\/isaamyloidosis.org\/files\/ISA%20recommendations%20Covid-19%20v_%203_3.pdf. Last Accessed April 21 2020"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25149"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13479","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13479","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:37:06Z","timestamp":1693564626000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/ejh.13479"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13479","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"2020-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}